Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd share price inched up 0.37% to Rs 804.2 after the company's net profit surged by 93.72% to Rs 333.9 crore, while revenue from operations gained significantly 21.11% to Rs 2603.48 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.73 lakh crore, easing 4.49%. It has improved by 1.84% over last one week and ticked higher by 1.37% in last one month while the market capitalization of Alembic Pharmaceuticals Ltd has marginally improved by 2.67% and 3.64% in the same period respectively. Profit before tax (PBT) of Alembic Pharmaceuticals Ltd stood at Rs 437.95 crore in Q3 FY26, jumping 95.76% year-on-year, and surging by 97.40% quarter-on-quarter. EBITDA came in at Rs 548 crore, expanding by 77.52% YoY and rallying 72.96% sequentially. Total expenses advancing by 11.77% to Rs 2141.01 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 599.64 crore, increasing 15.92% YoY, while employee benefits expense was at Rs 503.75 crore, ticking higher by 6.29% YoY. For the TTM ended FY26, revenue from operations rose 10.08% to Rs 7344.9 crore, while net profit registered a growth of 15.26% to Rs 670.83 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 100466% to Rs 1064.05 crore, and PBT saw a marginal contraction of 1.87% to Rs 693.95 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 782.73 crore in FY26, as against Rs 87.97 crore in FY25. Alembic Pharmaceuticals Ltd plunged by 12.99% in last one year, significantly underperforming the benchmark BSE Sensex which has softened by 8.41% during the same period.

Alembic Pharmaceuticals Limited will hold a board meeting on Wednesday, November 4, 2026, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026, the company said in a filing. The trading window for company securities, which was closed from October 1, 2026, will reopen 48 hours after the financial results are declared.

Alembic Pharmaceuticals Limited informed the Bombay Stock Exchange and National Stock Exchange of India that it received a certificate from MUFG Intime India Private Limited, formerly Link Intime India Private Limited, confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter and half year ended September 30, 2026.

Alembic Pharmaceuticals Limited informed the Bombay Stock Exchange and National Stock Exchange of India that the trading window for dealing in the company's securities will be closed from October 1, 2026, until 48 hours after the declaration of the un-audited financial results for the quarter and half year ending September 30, 2026, in accordance with SEBI regulations and the company’s code of conduct.

Alembic Pharmaceuticals Limited has appointed Mr. Chirag Shukla as Company Secretary & Compliance Officer (Key Managerial Personnel), effective August 20, 2026, according to a regulatory filing. Mr. Shukla, a qualified Company Secretary and Law Graduate with over 19 years of experience, previously worked at Deepak Phenolics Limited, Schaeffler India Limited, Alembic Limited and Bhavnagar Energy Company Limited.

Alembic Pharmaceuticals Ltd share price gained 1.14% to Rs 806.1 after the company's net profit dropped 14.47% to Rs 172.36 crore, while revenue from operations edged up 16.35% to Rs 2149.77 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.75 lakh crore, rising 6.24%. It has inched up 1.51% over last one week and moving up by 11.59% in last one month while the market capitalization of Alembic Pharmaceuticals Ltd has eased by 1.49% and 2.60% in the same period respectively. Profit before tax (PBT) of Alembic Pharmaceuticals Ltd stood at Rs 221.86 crore in Q2 FY26, jumping 16.70% year-on-year, and surging by 87.03% quarter-on-quarter. EBITDA came in at Rs 317 crore, expanding by 15.31% YoY and rallying 56.57% sequentially. Total expenses rose by 12.13% to Rs 1915.62 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 517.3 crore, witnessing a sharp rise of 27.97% YoY, while employee benefits expense was at Rs 473.94 crore, rising by 7.98% YoY. For the TTM ended FY26, revenue from operations grew 10.08% to Rs 7344.9 crore, while net profit improved by 15.26% to Rs 670.83 crore, compared to previous TTM. EBITDA soared by 100466% to Rs 1064.05 crore, and PBT softened 1.87% to Rs 693.95 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 782.73 crore in FY26, as against Rs 87.97 crore in FY25. Alembic Pharmaceuticals Ltd tumbled by 16.66% in last one year, underperforming the benchmark BSE Sensex which has eased by 2.94% during the same period.

Alembic Pharmaceuticals Limited reported a 26% increase in revenue from operations to Rs 2150 crore for the first quarter ended June 30, 2026, according to a revised press release. The company’s profit after tax rose 12% year-on-year to Rs 173 crore, with EBITDA pre R&D increasing to Rs 523 crore, representing a 24% margin, while the India Branded Business delivered 7% year-on-year growth, reaching Rs 642 crore in revenue. The US Formulation business grew by 49% to Rs 778 crore, with seven product launches in the US market during the quarter, and the API business increased by 33% to Rs 346 crore.

Alembic Pharmaceuticals Limited reported consolidated revenue from operations increased by 26% to Rs 2150 crore for the quarter ended June 30, 2026, with a profit after tax of Rs 173 crore, up 12% year-on-year, according to a press release. The company’s US formulation business grew by 49% to Rs 778 crore, driven by seven new product launches, while its India branded business increased 7% to Rs 642 crore, and the API business grew by 33% to Rs 346 crore.

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Prucalopride Tablets, 1 mg and 2 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA Inc. Prucalopride tablets are serotonin-4 receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.  Prucalopride Tablets, 1 mg and 2 mg, have an estimated market size of US$ 100 million for twelve months ending March 2026 according to IQVIA.

Alembic Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 4 August 2026.